Arbutus Biopharma Revenue and Competitors
Estimated Revenue & Valuation
- Arbutus Biopharma's estimated annual revenue is currently $10.2M per year.
- Arbutus Biopharma's estimated revenue per employee is $100,693
- Arbutus Biopharma's total funding is $142M.
- Arbutus Biopharma's current valuation is $447.7M. (January 2022)
Employee Data
- Arbutus Biopharma has 101 Employees.
- Arbutus Biopharma grew their employee count by 0% last year.
Arbutus Biopharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | General Counsel & Chief Compliance Officer | Reveal Email/Phone |
4 | Chief Scientific Officer | Reveal Email/Phone |
5 | Chief Operating Officer | Reveal Email/Phone |
6 | Chief Development Officer | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | EVP and General Counsel, Ph.D., J.D. | Reveal Email/Phone |
9 | VP, Biology | Reveal Email/Phone |
10 | VP Human Resources | Reveal Email/Phone |
Arbutus Biopharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11830M | 8030 | 26% | $2.7B | $83B |
What Is Arbutus Biopharma?
Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We believe that Arbutus' comprehensive HBV pipeline of drugs and drug candidates optimally positions us to transform the HBV treatment landscape and to capitalize on the HBV global market opportunity. We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy to cure HBV.
keywords:N/A
$142M
Total Funding
101
Number of Employees
$10.2M
Revenue (est)
0%
Employee Growth %
$447.7M
Valuation
N/A
Accelerator
Arbutus Biopharma News
Two analysts have provided estimates for Arbutus Biopharma's earnings. The highest sales estimate is $8.33 million and the lowest is $3.20...
Several research analysts recently commented on the stock. HC Wainwright raised their price target on shares of Arbutus Biopharma from $8.00 to...
Arbutus was created in 2015 through the merger of OnCore Biopharma of Doylestown and Tekmira Pharmaceutical Corp. of Vancouver. Today, Arbutus...
Other Companies in Warminster
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $31.1M | 101 | N/A | N/A |
#2 | $15M | 103 | -6% | $126.1M |
#3 | $20M | 111 | -4% | N/A |
#4 | $17.4M | 112 | -8% | N/A |
#5 | $7.5M | 128 | 12% | N/A |